Key facts
- This page summarizes Jennifer E. Cook's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 8 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 Jul 2026, 16:40.
Jennifer E. Cook - 09 Jul 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- Director
- Issuer ticker
- BBIO
- Reported as of
- 09 Jul 2026
- Net transaction value
- -$13,156,008
- SEC form
- 4
- Accepted by SEC
- 13 Jul 2026, 16:40:35 UTC
- Prior SEC filing
- 24 Jun 2026
- Next SEC filing
- 07 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Will Solis, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jennifer E. Cook filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 13 Jul 2026.
Change
- Previous filing in this sequence was filed on 24 Jun 2026.
- Current net transaction value: -$13,156,008.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001754371
Primary reporting owner
Cook Jennifer E.
- Relationship
- Director
- Address
- C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
- Signature
- /s/ Will Solis, Attorney-in-Fact
- Signature date
- 13 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +19,000
- Change %
- +227%
- Price
- $8.45*
- Shares after
- 27,383
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +112,422
- Change %
- +411%
- Price
- $29.00*
- Shares after
- 139,805
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +17,167
- Change %
- +12%
- Price
- $16.75*
- Shares after
- 156,972
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Sale
- Transaction value
- $3,038,028
- Shares
- -36,167
- Change %
- -23%
- Price
- $84.00
- Shares after
- 120,805
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Sale
- Transaction value
- $10,117,980
- Shares
- -112,422
- Change %
- -93%
- Price
- $90.00
- Shares after
- 8,383
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -19,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,000
- Exercise price
- $8.45
- Footnotes
- F1, F2
BBIO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -112,422
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 112,422
- Exercise price
- $29.00
- Footnotes
- F1, F3
BBIO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -17,167
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,167
- Exercise price
- $16.75
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
Footnote F2
1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
Footnote F3
The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
Footnote F4
1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.